The purpose of this study is to compare urinary and bowel side effects of hypofractionated radiotherapy in 20 treatments (4 weeks) to ultra- hypofractionated radiotherapy in 5 treatments (2 weeks) for prostate cancer that has returned after prostatectomy.
Learn more about the trial details in this informational video:
Total numerical dose differs in each arm but is considered biologically equivalent to each other and protracted fractionated radiotherapy (8 weeks).The investigators are also interested in looking at progression-free survival and the quality of life (health scores). The standard treatment for men with detectable PSA (biochemical recurrence) after radical prostatectomy is salvage radiotherapy (radiation after detectable PSA). Salvage radiotherapy delays the need for chronic, non-curative treatment, such as long-term androgen suppression, and is the only potentially curative treatment of some biochemical recurrences after prostatectomy. Standard treatment regimens range from 20-40 treatments.
Patients are recommended to undergo salvage radiotherapy delivered over many weeks, representing a high burden of therapy. Modern radiotherapy has been afforded many advantages including advanced image-guided radiotherapy allowing for larger dose delivery in fewer treatments and smaller margins with hypofractionated (20 treatments) and ultra-hypofractionated (5 treatments) radiotherapy. In patients that need salvage radiotherapy, the potential advantages of hypofractionated and ultrahypofractionated radiotherapy delivered over 20 or 5 treatments are: